Analyst Ratings For NASDAQ:PDLI – PDL BioPharma (NASDAQ:PDLI)
Today, Cowen reiterated its Hold rating on NASDAQ:PDLI – PDL BioPharma (NASDAQ:PDLI) with a price target of $2.50.
Some recent analyst ratings include
- 6/14/2018-Cowen Reiterated Rating of Hold.
- 8/10/2017-Piper Jaffray Companies Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:PDLI – PDL BioPharma (NASDAQ:PDLI)
NASDAQ:PDLI – PDL BioPharma (NASDAQ:PDLI) has insider ownership of 2.30% and institutional ownership of 90.55%.
- On 3/24/2017 Peter S Garcia, VP, bought 25,000 with an average share price of $1.98 per share and the total transaction amounting to $49,500.00.
- On 8/9/2016 Peter S Garcia, VP, bought 10,000 with an average share price of $3.00 per share and the total transaction amounting to $30,000.00.
- On 12/15/2015 Peter S. Garcia, CFO, bought 5,000 with an average share price of $3.64 per share and the total transaction amounting to $18,200.00.
- On 12/14/2015 Peter S. Garcia, CFO, bought 10,000 with an average share price of $3.42 per share and the total transaction amounting to $34,200.00.
- On 12/7/2015 Steffen Pietzke, CAO, bought 20,590 with an average share price of $3.64 per share and the total transaction amounting to $74,947.60.
- On 8/14/2015 Peter S Garcia, CFO, bought 20,000 with an average share price of $5.83 per share and the total transaction amounting to $116,600.00.
- On 11/26/2014 Harold E Selick, Director, bought 6,000 with an average share price of $8.08 per share and the total transaction amounting to $48,480.00.
Recent Trading Activity for NASDAQ:PDLI – PDL BioPharma (NASDAQ:PDLI)
Shares of NASDAQ:PDLI – PDL BioPharma closed the previous trading session at 2.69 down -0.01 0.37% with 2.674999952316284 shares trading hands.